Search Results for: Majority of Oncology Clinical Trials
Articles
Fortress Biotech Announces Initiation of Phase 3 Studies September 15, 2020
Fortress Biotech, Inc. recently announced that Caelum Biosciences, Inc., in collaboration with Alexion Pharmaceuticals, Inc., initiated the Cardiac Amyloid Reaching...PEPTIDE THERAPEUTICS - Oral Peptide Therapeutics – Opportunities Abound as Barriers Fall August 31, 2020
John S. Vrettos, PhD, says numerous technologies are currently in development that are designed to enable the oral delivery of peptides. Though each has its unique set of properties and capabilities, all must overcome key obstacles to successfully deliver peptides via the oral route.
Scioto Biosciences Receives $26.5 Million Series B Investment From Genome & Company August 12, 2020
Scioto Biosciences recently announced the closing of a strategic investment of up to $26.5 million from Genome & Company and other investors to join in an upcoming tranche….
Croda Strengthens Position in Life Sciences With Acquisition of Avanti Polar Lipids July 9, 2020
Croda International Plc recently announced it has agreed to acquire Avanti Polar Lipids, Inc., a knowledge-intensive leader in lipid-based drug delivery technologies for next-generation pharmaceuticals…..
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Specialized Capabilities for Small & Large Molecules June 4, 2020
Contributor Cindy H. Dubin interviews key players in the CDMO market who present case studies about how they are helping pharmaceutical and biopharma companies overcome a variety of formulation and manufacturing challenges.
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University May 13, 2020
Fortress Biotech, Inc. recently announced that Oncogenuity, Inc. has entered into an exclusive worldwide licensing agreement with Columbia University to develop novel….
PERSONALIZED MEDICINE - Personalizing Cancer Immunotherapy: Trends in Biomarker Discovery January 14, 2020
Emile Youssef, MD, PhD, says due to tumor heterogeneity, the plasticity and diversity of cancer cells, and a multitude of other factors, biomarker development is a challenge, and thus explores four trends in cancer biomarker discovery.
TYME Announces First Patient Dosed in Pivotal Trial January 9, 2020
Tyme Technologies, Inc. recently announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal...Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center September 5, 2019
Kaleido Biosciences, Inc. recently announced plans to develop Microbiome Metabolic Therapies (MMT) to enhance the effects of cancer immunotherapies under a new…….
Lipomedix Announces Initiation of Phase 1b Trial March 7, 2019
Lipomedix recently announced the initiation of a Phase 1b multicenter trial (LIPORAD-2018) to identify the optimal dose, safety, and efficacy...Intensity Therapeutics Highlights Data in Advanced Solid Tumors November 12, 2018
Intensity Therapeutics, Inc. recently announced additional data from a Phase 1/2 clinical study of INT230-6, the company’s novel lead product candidate...EXECUTIVE INTERVIEW - JRF Global: Innovating Drug Discovery & Development Solutions for Your Leads October 2, 2018
Sameer Navalgund, Global Director at JRF Global, shares his perspective about the on-going trends, current status, and some of the upcoming biggest challenges in the contract services industry.
FDA Accepts Larotrectinib NDA & Grants Priority Review June 6, 2018
Loxo Oncology, Inc. recently announced the US FDA has accepted the company’s New Drug Application (NDA) and granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: CDMOs Are Innovating for 21st-Century Medicine June 6, 2018
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs about the innovations they are developing for next-generation patient care, and how many are making investments that are enabling them to offer more services under one roof.
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead March 16, 2018
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics companyGlobalData.
DNA THERAPEUTICS - DNAbilize-ING Antisense March 15, 2018
Peter Nielsen, MBA, explains how his company’s candidates are differentiated from those in development at other companies by the type of modification to the antisense molecule and the method by which it is conveyed to its target cell.
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead February 28, 2018
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics...Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology February 13, 2018
Rexahn Pharmaceuticals, Inc. recently announced it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd....GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program September 7, 2017
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option...Galena Biopharma Enters Merger Agreement With SELLAS Life Sciences August 14, 2017
Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd recently announced they have entered into an all stock definitive merger...
